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1  | INTRODUC TION
The limited availability of suitable donor organs impedes transplan-
tation as a curative therapy for heart failure.1 The ventricular assist 
device (VAD) is increasingly used as a bridge to transplantation to 
increase survival while waiting for a compatible organ. VAD is ef-
fective in prolonging survival of patients with heart failure, enabling 
70% of patients to bridge to subsequent heart transplant.1 The 
effectiveness of VAD has led to increased use, with 19% of heart 
transplants in the United States between 2004 and 2014 bridged to 
 
Received:	6	September	2019  |  Revised:	29	November	2019  |  Accepted:	9	December	2019
DOI: 10.1111/ctr.13772  
O R I G I N A L  A R T I C L E
Factors influencing transfusion-associated HLA sensitization 
in patients bridged to heart transplantation using ventricular 
assist device
Jae Elkind1 |   Juliana Sobczyk1 |   Oscar Ostberg-Braun2 |   Jorge Silva Enciso2 |   
Eric Adler2 |   Gerald P. Morris1
Elkind and Sobczyk contributed equally to this work. 
1Department of Pathology, University of 
California, San Diego, La Jolla, CA, USA
2Department of Medicine, University of 
California, San Diego, La Jolla, CA, USA
Correspondence
Gerald P. Morris, Department of Pathology, 
University of California San Diego, La Jolla, 
CA 92093.
Email: gpmorris@ucsd.edu
Abstract
Background: Bridging heart failure patients with mechanical ventricular assist devices 
(VAD) enables access to transplantation. However, VAD is associated with increased 
risk for anti-HLA antibodies associated with rejection of subsequent allografts. 
Factors determining alloantibody formation in these patients remain undefined.
Methods: We performed a single-center retrospective cohort study of 164 patients 
undergoing heart transplantation from 2014 to 2017. Medical records including use 
of VAD, transfused blood products, anti-HLA antibody testing, crossmatch, and time 
to transplant were evaluated.
Results: Patients received an average of 13.8 red blood cell and 1.9 single-donor 
platelet units associated with VAD. There was a 28.7% increase in the incidence of 
anti-HLA antibodies after VAD. Development of anti-HLA antibodies did not cor-
relate with volume or type of blood products, but with pre-VAD HLA sensitization 
status; relative risk of new alloantibodies in patients with pre-VAD antibodies was 
3.5-fold higher than those without prior antibodies (P = .008). Development of new 
anti-HLA antibodies was associated with an increased time to transplant (169 vs 
330 days, P = .013).
Conclusions: Our findings indicate that the presence of anti-HLA antibodies pre-VAD 
was the most significant risk factor for developing additional antibodies post-VAD, 
suggesting that a subset of patients may be predisposed to alloantibody formation.
K E Y W O R D S
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transplant using VAD. Though VADs are an effective bridge therapy, 
they are associated with distinct complications that affect subse-
quent transplantation. In addition to complications associated with a 
major surgery such as bleeding and infection, there is a debated im-
munologic risk. VAD support has been associated with development 
of antibodies against HLA alloantigens.2-8
The presence of anti-HLA antibodies has serious adverse con-
sequences for patients awaiting heart transplantation. Antibodies 
against donor HLA class I and class II antigens are definitively as-
sociated with antibody-mediated rejection and allograft failure 
and associated with increased mortality.9-13 Reported rates of 
alloimmunization following VAD placement are variable, ranging 
from 28% to 66% of patients.2,4,14,15 Transfusion of cellular blood 
products is known risk factors for HLA-allosensitization, with re-
ported sensitization rates of 17%-15% for packed red blood cell 
(PRBC) units and 28%-55% for single-donor platelet (SDP) units.16 
Patients undergoing VAD surgery have a nearly universal ex-
posure to blood products, receiving a median of 8 PRBCs and 2 
SDPs.6,17-19 This provides ample exposure to alloantigens, though 
direct associations between blood product exposure and risk for 
development of alloantibodies in the setting of VAD remain elu-
sive.14,20-22 However, reported rates of HLA alloimmunization as-
sociated with VAD are higher than for general transfusion, with 
reports of sensitization rates up to 66%.2,4,14,15 Similar effects 
have not been observed for extracorporeal membrane oxygen-
ation, suggesting a unique effect of VAD to promote alloantibody 
formation. Given the undefined effects of VAD on alloimmuniza-
tion, we investigated transfusion associated with VAD implanta-
tion with the goal of identifying risk factors for anti-HLA antibody 
formation.
2  | METHODS
2.1 | Study population
Records for 164 adult patients undergoing heart transplanta-
tion (n = 107 patients undergoing VAD implantation as a bridge 
to transplantation, n = 57 non-VAD patients) at the University 
of California San Diego between January 2014 and September 
2017 were retrospectively reviewed (Table 1). Transfusion data 
were available for all 164 heart transplant patients. Of the 107 
VAD patients, both pre-VAD and subsequent post-VAD antibody 
data were available in 59 patients (n = 84 pre-VAD antibody data, 
n = 61 post-VAD antibody data). Electronic medical records and 
laboratory records were reviewed for perioperative (day 0-3 fol-
lowing VAD insertion) blood product utilization, and anti-HLA an-
tibody testing (most recent pre-VAD placement and 2-12 weeks 
after VAD placement) and cellular crossmatch testing results. 
Clinical records were reviewed for patient demographics and clini-
cal events related to VAD implantation and heart transplantation. 
All study procedures were conducted under the approval and su-
pervision of institutional IRB.
2.2 | Anti-HLA antibody testing
All patient serum samples were collected and tested as part of stand-
ard of care treatment according to the existing protocols. Patients 
were screened for anti-HLA antibodies using FlowPRA Class I and 
Class II assays (One Lambda) using FACSCanto or FACSCalibur 
instruments (BD Biosciences). Anti-HLA antibodies detected by 
FlowPRA were identified using LABScreen Single Antigen HLA Class 
I and Class II bead assays using a Labscan 200 (Luminex). Data were 
analyzed using HLA Fusion software (One Lambda). Antibodies with 
normalized	mean	fluorescence	intensity	(MFI)	≥3000	were	identified	
as positive, based upon likelihood of causing a positive flow cyto-
metric crossmatch.23
2.3 | Cellular crossmatch testing
Donor lymphocytes isolated from peripheral blood, spleen, or 
lymph node samples by density gradient separation using Rosette-
Sep Lymphocyte Enrichment kit (StemCell Technologies) were 
treated with 2 mg/mL pronase (Sigma) for 20 minutes at 37°C. 
Donor cells were incubated in duplicate with current (typically 
<30 days old) and historical peak (maximum cPRA within the last 
12 months) recipient serum for 20 minutes at room temperature. 
Cells were labeled with anti-CD3 PerCP (SK7; BD Biosciences) 
anti-CD19 PE (SJ25-C1; BD Biosciences), and goat F(ab’)2 anti-
human IgG FITC (Jackson) for 20 minutes at 4°C, washed, and 
analyzed using a FACSCalibur or FACSCanto. Alloantibody binding 
was determined by calculating mean channel shift (MCS) of cells 
incubated with patient serum as compared to cells incubated with 
TA B L E  1   Patient demographics
 VAD patients
Heart transplant patients 
not receiving VAD
N 107 57
Age (mean, range) 58.7 (19-80) 52.0 (19-73)
Gender (% female) 15.0 14.0
Ethnicity (%)
Asian 6.5 10.5
African American 12.1 8.8
Caucasian 42.0 33.3
Hispanic 31.8 43.9
Native	American 2.8 3.5
Other/Unknown 4.7 0
Diagnosis (%)
Ischemic 
cardiomyopathy
51.4 28.1
Non-ischemic	
cardiomyopathy
45.8 43.9
Congenital 0 14.0
Other 2.8 14.0
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control	 normal	 human	 serum;	MCS	≥16	was	 considered	positive	
for	T-cell	FCXM	and	MCS	≥32	was	considered	positive	for	B	cell	
FCXM.
2.4 | Statistical analysis
Calculated PRA (cPRA) percentages were calculated entering all un-
acceptable	antigens	 for	HLA-A,	 -B,	 -C,	 -DR,	and	 -DQ	 in	 the	UNet	
computer system at the US Department of Health and Human 
Services	Organ	Procurement	and	Transplantation	Network	website	
(http://optn.trans plant.hrsa.gov). Categorical data were analyzed 
using Fisher's exact test and chi-square test for multifactor analysis, 
numerical data were analyzed using the Mann-Whitney test and the 
Wilcoxon signed-rank test for paired samples, and survival analysis 
was performed by the Gehan-Breslow-Wilcoxon test using Prism 7 
(Graph Pad).
3  | RESULTS
3.1 | VAD placement results in increased anti-HLA 
antibodies
To examine the effect of VAD on sensitization against allogeneic 
HLA, we compared the incidence of anti-HLA antibodies in patients 
before (n = 84) and after VAD implantation (n = 61) (Figure 1A). The 
proportion of patients testing positive for any anti-HLA antibod-
ies	 predicted	 to	 cause	 a	 positive	 cellular	 crossmatch	 (MFI	 ≥3000)	
increased from 34.5% in the pre-VAD population to 63.2% in the 
post-VAD population (P = .001). Direct comparison of pre-VAD and 
post-VAD anti-HLA antibodies by individual patients (n = 59) dem-
onstrated that VAD placement was associated with the develop-
ment of new antibodies against both HLA class I and class II antigens 
(Figure 1B). This resulted in a significant increase in risk for immuno-
logic incompatibility with potential donors as measured by increased 
cPRA (Figure 1C).
3.2 | Development of anti-HLA antibodies after 
VAD significantly delays subsequent transplantation
Development of anti-HLA antibodies decreases the pool of immu-
nologically compatible donors, potentially hindering subsequent 
transplant. To evaluate the potential effect of new anti-HLA anti-
bodies formed after VAD placement on subsequent transplantation, 
we compared the time from VAD placement to transplant between 
patients who developed new anti-HLA antibodies (n = 19) and those 
who did not (n = 40) (Figure 2). Patients developing new alloantibod-
ies had a significant delay in subsequent transplantation. Patients 
who developed new anti-HLA antibodies post-VAD implantation 
waited an average of 330 days for a heart transplantation vs the av-
erage wait time of 169 days for patients who did not develop new 
anti-HLA antibodies (P = .013). Review of crossmatch testing dem-
onstrated that patients having developed anti-HLA antibodies after 
VAD were twice as likely to have a positive crossmatch against a 
potential donor as compared to patients who did not develop anti-
bodies after VAD (36.4% vs 15.6%, P = .031). This resulted in having 
to evaluate more potential donors in order to find an immunologi-
cally compatible organ (2.6 ± 1.6 donors tested/transplanted organ) 
in patients with new anti-HLA antibodies as compared with those 
who did not develop additional antibodies after VAD implantation 
(1.1 ± 1.1). This increase does not take into account organ offers 
that may have been deemed unlikely to be immunologically com-
patible	based	on	UNET	avoid	 antigen	 listing	or	 virtual	 crossmatch	
analysis. VAD patients had a higher rate of false-positive reactivity 
that was eliminated with DTT serum treatment compared with heart 
transplant patients that did not receive VAD therapy (30.4% in VAD 
patients vs 5.9% in patients without VAD, P = .107). However, the in-
creased frequency of positive crossmatches for patients developing 
anti-HLA antibodies after VAD was not attributable to non-specific 
antibody reactivity, as both groups had similar rates of conversion of 
positive cellular crossmatch to negative with serum DTT treatment 
(31.3% in patients with new antibodies vs 28.6% in patients without 
new antibodies, P = 1.000).
3.3 | Transfusion associated with VAD
Formation of antibodies against HLA alloantigens results from 
specific sensitizing events such as transplantation, transfusion, or 
pregnancy. Given the high degree of exposure to blood products 
associated with thoracic surgery for VAD placement, we sought to 
evaluate whether there is a product-specific or dose-dependent re-
lationship between peri-VAD surgery transfusion and anti-HLA an-
tibody formation. Review of transfusion records for all VAD patients 
demonstrated that 100/107 (93.5%) of patients received at least 
one PRBC or SDP unit temporally associated with VAD placement 
(defined as either during surgery or within 3 days after surgery). 
Average transfusion support included 9.6 ± 9.9 total cellular blood 
products including 7.8 ± 9.1 PRBC units and 1.8 ± 1.9 SDP units 
(Figure 3A), similar to reported rates of transfusion associated with 
VAD placement. These data confirm the significant exposure risk for 
alloimmunization by transfusion in patients receiving VAD therapy.
To evaluate the risk of anti-HLA antibody formation associated 
with VAD-associated transfusion, we correlated formation of new 
anti-HLA antibodies in the 59 patients for which pre- and post-
VAD anti-HLA antibody testing was available with PRBC and SDP 
transfusion.	 New	 anti-HLA	 antibodies	 were	 detected	 in	 25/56	
(44.6%) of patients receiving PRBCs (468 total units transfused), 
18/44 (40.9%) of patients receiving SDPs (117 total units trans-
fused), and 27/59 (45.8%) of transfused patients. Patients that de-
veloped new anti-HLA antibodies associated with VAD placement 
did not demonstrate any differences in exposure to transfused 
PRBC and SDP compared to patients that did not develop anti-
bodies (Figure 3B). The number of new anti-HLA antibodies did 
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not demonstrate significant correlation with the unit exposure to 
PRBCs (r = .014, P = .912), SDPs (r = .075, P = .651), or total trans-
fusion (r = .072, P = .586).
3.4 | Factors influencing alloantibody formation
Given the absence of a dose-dependent correlation between cel-
lular blood product transfusion and formation of anti-HLA anti-
bodies, we next investigated patient-specific factors that could 
explain differential alloantibody formation (Table 2). There were 
no significant differences in age, gender, ethnicity, underlying di-
agnosis, or type of VAD used between patients that developed 
new anti-HLA antibodies compared to those that did not (n = 19 
patients who developed new anti-HLA antibodies, n = 40 patients 
who did not develop new anti-HLA antibodies). However, 10/19 
(52.6%) of patients developing new anti-HLA antibodies after VAD 
placement had other pre-existing anti-HLA antibodies compared 
with only 6/40 (15.0%) of patients who did not develop new al-
loantibodies (P = .004). Given that our laboratory uses a cutoff 
value of 3000 MFI to identify positive anti-HLA antibodies, it is 
conceivable that antibodies evident as positive after VAD place-
ment were present at lower levels and increased in response to al-
logeneic stimulation by transfusion. To evaluate this, we compared 
the MFI for each antibody detected by solid-phase immunoassay 
on samples prior to and following VAD placement (Figure 4). Of 
the 19 patients who were new anti-HLA antibody formers post-
VAD implantation, a total of 90 new alloantibodies were detected. 
A majority (65/90, 72.2%) of these new antibodies developed in 
the absence of previously detectable antibodies as indicated by 
MFI values <1000 on pre-VAD testing. Of the remaining 25 an-
tibodies (27.8%), 9/90 (10.0%) had pre-VAD MFIs between 2000 
and 3000 and 16/90 (17.8%) had pre-VAD MFIs between 1000 
and 2000. We interpret the second group as reflecting a memory 
immune response against alloantigens to which the patient had 
been previously sensitized. Together, these data suggest that pa-
tients who have a history of forming anti-HLA antibodies after 
prior alloimmunization are at increased risk (OR = 6.30, 95% CI 
1.24-4.34) for development of anti-HLA antibodies associated 
with VAD placement.
4  | DISCUSSION
Alloantibodies present a significant obstacle to heart transplanta-
tion. Anti-HLA antibodies are present in as much as 43% of pa-
tients awaiting heart transplantation, reducing the number of 
immunologically compatible organs from among the already lim-
ited pool of potential donors.1 VAD devices are an effective and 
widely used method for improving cardiac function in patients with 
heart failure. Unfortunately, VAD use is associated with develop-
ment of anti-HLA antibodies which hinder subsequent transplanta-
tion.2-8 Experience from our center mirrors this, with significantly 
increased incidence of anti-HLA antibodies after VAD placement 
(Figure 1). Importantly, development of new anti-HLA antibodies 
after VAD placement presented a significant obstacle to identifica-
tion of an immunologically compatible organ, delaying subsequent 
transplantation wait times twofold compared to those without new 
F I G U R E  1   Ventricular assist device (VAD) implantation is associated with increased anti-HLA antibodies. A, Comparison of anti-HLA 
antibodies detected by solid-phase immunoassays in patients prior to VAD implantation or in patients 1-3 mo after VAD placement. B, 
Comparison of antibodies against HLA class I and class II antigens detected in pre- and post-VAD samples for individual patients. Groups 
compared using the Wilcoxon signed-rank test. C, Change in overall allosensitization evaluated by cPRA calculated from individual 
alloantibodies detected in pre- and post-VAD samples. Groups compared using the Wilcoxon signed-rank test
(A) (B) (C)
F I G U R E  2   Development of anti-HLA antibodies after VAD 
placement is associated with an increased time to subsequent 
transplant. Death-censored time to transplant for patients 
developing or not developing additional anti-HLA antibodies after 
VAD placement. Curves compared using the Gehan-Breslow-
Wilcoxon test
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anti-HLA antibody formation (Figure 2), similar to effects in other 
studies.6,21 Thus, we sought to identify underlying risk factors that 
might enable risk stratification or risk avoidance measures.
Ventricular assist device-associated antibodies can be split 
into two categories, non-specific antibodies and HLA-specific 
alloantibodies. Production of non-specific antibodies associated 
with VAD has been attributed to bystander activation of B cells 
due to a “pro-inflammatory” environment caused by turbulent 
blood	 flow	 and	 reactivity	 to	 the	 VAD.	 Non-specific	 antibodies	
can cause positive reactions in cellular crossmatch and alloan-
tibody immunoassays, though their clinical significance appears 
to be limited.4,5,22,24 Consistent with this, we observe non-spe-
cific antibodies as evidenced by high background in solid-phase 
immunoassays and cellular crossmatching, though the effects 
of these are limited by routine use of EDTA serum treatment in 
solid-phase immunoassay and DTT serum treatment in cellular 
crossmatch. Of greater concern are antibodies with definable 
specificities against allogeneic HLA which can mediate AMR and 
allograft loss.9-13
Development of antibodies against allogeneic HLA requires sen-
sitization against specific alloantigen. Alloimmunization can occur 
through pregnancy, transfusion of cellular blood products, or prior 
F I G U R E  3   Differential exposure to cellular blood components 
does not explain development of anti-HLA antibodies associated 
with VAD placement. A, Frequency of patients receiving indicated 
doses of PRBC and SDP products. B, Comparison of blood product 
exposure for patients developing or not developing new anti-HLA 
antibodies. Groups compared using the Mann-Whitney test
(A)
(B)
TA B L E  2   Risk factors for alloimmunization
 
No new antibodies
n = 40
New anti-HLA 
antibodies
n = 19
Age (y) 56.2 ± 12.3 55.9 ± 13.5
P = .838
Female (%) 12.5 21.1
P = .438
Ethnicity (%)
Asian 5.0 5.3
African American 12.5 5.3
Caucasian 40.0 47.4
Hispanic 35.0 26.2
Native	American 5.0 5.3
Other/Unknown 2.5 10.5
  P = .757
Diagnosis (%)
Ischemic 
cardiomyopathy
35.0 52.6
Non-ischemic	
cardiomyopathy
55.0 47.4
Congenital 0 0
Other 10.0 0
  P = .220
VAD type (%)
HVAD 40.0 57.9
HM II 35.0 21.1
HM III 7.5 10.5
BiVAD 17.5 10.5
  P = .465
Pre-VAD anti-HLA 
Antibodies (n, %)
6 (15.0) 10 (52.6)
  P = .004
F I G U R E  4  New	anti-HLA	antibodies	detected	after	VAD	
represent both de novo and memory immune responses. 
Comparison of MFI for individual HLA specificities detected by 
single-antigen immunoassay in pre- and post-VAD samples for 
patients with new antibodies detectable after VAD placement. 
Dotted line at 1000 MFI represents upper limit for antibodies 
considered not present in pre-VAD samples (de novo). Dotted line 
at 3000 MFI represents upper limit for antibodies considered to be 
present but not “positive” in pre-VAD samples (memory)
0
1000
2000
3000
5000
10000
15000
20000
M
FI
 (N
or
m
al
iz
ed
)
Pre-VAD     Post-VAD
"Memory" 27.8%
De novo   72.2%
New positive anti-HLA antibodies 
after VAD implantation
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transplant.16 Given the nearly ubiquitous exposure risk as well as the 
viability of blood product exposure as a modifiable risk factor, we in-
vestigated cellular blood product exposure at the time of VAD place-
ment as a risk factor for development anti-HLA antibodies. Analysis 
of cellular blood product exposure for patients in our study did not 
reveal a relationship between exposure dose and risk of alloimmuni-
zation (Figure 3). Direct association between cellular blood product 
exposure and development of antibodies following VAD implantation 
has proven similarly elusive in other studies for several reasons, in-
cluding the nearly universal exposure to cellular blood products and 
variability in the origin and composition of cellular blood products 
(ie, leukoreduced or non-leukoreduced PRBCs, SDPs vs multi-donor 
platelet units, irradiated or non-irradiated units). The most suggestive 
of these studies have indicated a higher risk of allommunization in VAD 
patients resulting from platelets20,21 and a decreased risk associated 
with leukoreduced PRBCs.14,16,20,25. However, other studies saw no 
relationships between transfusion exposure and alloimmunization.22
Comparison of previously studied risk factors for anti-HLA 
antibody incidence did not demonstrate significant differences 
between patients developing anti-HLA antibodies and those not 
developing antibodies related to gender, ethnicity, or type of VAD 
used (Table 2). Much like other studies in thoracic organ trans-
plantation, our study is limited by sample size, especially when 
comparing transplantation wait times (data available for 55% of 
patients, 59/107). This increases the probability of a type II error, 
which could lead to rejection of possibly relevant clinical factors 
that our study is not powered to confidently identify. However, 
we observed significantly increased risk for new anti-HLA anti-
bodies in patients with prior evidence of alloimmunization. Other 
studies have observed similarly increased risk for anti-HLA anti-
body formation in patients with a history of detectable anti-HLA 
antibodies.6,25 Our findings that 72.2% of new anti-HLA antibod-
ies having pre-VAD MFIs 0-1000 (Figure 4) are suggestive that a 
majority of anti-HLA antibodies that arise after VAD placement 
and associated transfusion may do so as new immune responses 
to VAD-associated sensitization. Our data cannot definitively rule 
out the possibility that these newly detected antibodies are not a 
result of memory immune responses, particulary since they occur 
in patients with other anti-HLA antibodies (demonstrating prior 
sensitization). Together, these data support a conclusion that the 
detection of anti-HLA antibodies is predictive of an increased risk 
for subsequent development of additional anti-HLA antibodies. 
This suggests there may be factors that predispose some patients 
to form alloantibodies, in the context of VAD but also in a more 
general manner. Future studies identifying such factors would be 
of particular interest to facilitate focused risk reduction strategies 
as well as possibly identify actionable targets to inhibit alloimmu-
nization. Given the absence of a well-defined association between 
cellular blood product exposure, VAD placement, and alloimmuni-
zation, it is likely prudent to continue with current best practice 
guidelines for general blood conservation in thoracic surgery26 and 
exclusive use of leukoreduced PRBCs27 to minimize potential risk 
for alloimmunization.
It is worth noting that primary outcomes in this study included 
anti-HLA antibody formation as well as time to transplant. We do 
not have complete post-transplant anti-HLA antibody and clini-
cal outcomes data for this cohort, and were thus unable to ana-
lyze mortality and the incidence of antibody-mediated rejection. 
Questions regarding the impact of pre-transplant alloimmunization 
on post-transplant outcomes are of interest for future study. We hy-
pothesize that patients who are sensitized to alloantigens as a result 
of VAD therapy could be at risk for post-transplant donor-specific al-
loantibody formation and resulting higher morbidity and mortality. A 
recent study28 reported the outcome of patients with high immuno-
logical risk defined by pre-transplant donor-specific antibodies that 
were managed with a post-transplant prophylactic strategy instead 
of desensitization. The results of our study suggest that it may be of 
interest to propose applying such a strategy to patients identified as 
“at risk” based on immunologic response to pre-transplant alloimmu-
nization against non–donor-specific HLA.
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